Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis

NCT06106672 is registered in ClinicalTrials.gov with COUR Pharmaceutical Development Company, Inc. as lead sponsor.

NCT NCT06106672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06106672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 30, 2024
Completion date
August 31, 2026
Enrollment
54 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

achr myasthenia gravis, generalized myasthenia, musk mg, myasthenia gravis